--- title: "Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th" type: "News" locale: "en" url: "https://longbridge.com/en/news/298168859.md" description: "Attovia Therapeutics' (NASDAQ:ATTO) quiet period ends September 14th, following its $289M IPO on August 5th. Post-quiet period, underwriters are expected to initiate research coverage. Five analysts recently started coverage with 'Buy' or 'Overweight' ratings and price targets ranging from $30 to $52, averaging $42.20. Insiders Goldman Sachs and Global Strategic Fund increased holdings in early August. The company reported Q2 EPS of ($4.88) on $0.45M revenue." datetime: "2026-09-07T05:20:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298168859.md) - [en](https://longbridge.com/en/news/298168859.md) - [zh-HK](https://longbridge.com/zh-HK/news/298168859.md) generator: "portal-rs" --- # Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14th Attovia Therapeutics' (NASDAQ:ATTO - Get Free Report) quiet period will end on Monday, September 14th. Attovia Therapeutics had issued 17,000,000 shares in its IPO on August 5th. The total size of the offering was $289,000,000 based on an initial share price of $17.00. During Attovia Therapeutics' quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. Get **Attovia Therapeutics** alerts: ## Wall Street Analyst Weigh In Several research analysts have recently weighed in on ATTO shares. Morgan Stanley started coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an "overweight" rating and a $39.00 price target for the company. Citigroup started coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set a "buy" rating and a $30.00 price objective on the stock. Royal Bank Of Canada started coverage on Attovia Therapeutics in a report on Monday, August 31st. They issued an "outperform" rating and a $45.00 price objective for the company. Leerink Partners assumed coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an "outperform" rating and a $52.00 target price for the company. Finally, Lifesci Capital began coverage on shares of Attovia Therapeutics in a research note on Monday, August 31st. They set an "outperform" rating and a $45.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $42.20. **Check Out Our Latest Research Report on ATTO** ## Attovia Therapeutics Stock Performance NASDAQ ATTO opened at $25.55 on Monday. Attovia Therapeutics has a 1-year low of $16.15 and a 1-year high of $27.66. Attovia Therapeutics (NASDAQ:ATTO - Get Free Report) last released its quarterly earnings results on Wednesday, September 2nd. The company reported ($4.88) earnings per share (EPS) for the quarter. The firm had revenue of $0.45 million during the quarter. As a group, analysts forecast that Attovia Therapeutics will post -4.06 earnings per share for the current fiscal year. ## Insiders Place Their Bets In other Attovia Therapeutics news, major shareholder Goldman Sachs Group Inc bought 500,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The stock was acquired at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the acquisition, the insider owned 3,020,632 shares in the company, valued at approximately $51,350,744. This represents a 19.84% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio acquired 382,352 shares of Attovia Therapeutics stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $17.00 per share, with a total value of $6,499,984.00. Following the completion of the purchase, the insider directly owned 4,181,367 shares in the company, valued at $71,083,239. This represents a 10.06% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 2,740,587 shares of company stock valued at $47,269,979. ## Attovia Therapeutics Company Profile (Get Free Report) Attovia Therapeutics, Inc NASDAQ: ATTO is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs. Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways. ## See Also - Five stocks we like better than Attovia Therapeutics - AI Token Costs Are Changing the Hardware vs. Software Debate - 3 ETFs That Could Move as Rate Expectations Shift - 3 Stocks With September Catalysts Investors Shouldn’t Ignore - Ollie's Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Attovia Therapeutics Right Now? Before you consider Attovia Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Attovia Therapeutics wasn't on the list. While Attovia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) ## Related News & Research - [Attovia Therapeutics (NASDAQ:ATTO) Upgraded by Royal Bank Of Canada to "Moderate Buy" Rating](https://longbridge.com/en/news/297636916.md) - [Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27](https://longbridge.com/en/news/297941843.md) - [Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway](https://longbridge.com/en/news/297940103.md) - [ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030](https://longbridge.com/en/news/297826808.md) - [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**